Lakefront Biotherapeutics NV current report, Q1 FY2022

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of February 2022. The filing serves to incorporate by reference a press release dated February 2, 2022 (Exhibit 99.1), which is attached to the report. The registrant is a foreign private issuer incorporated in Belgium.

Key Financial Metrics

The filing text provided does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.

Material Changes

The filing does not detail material changes in financial performance or operations. It references a press release issued on February 2, 2022, but the content of that release is not included in the provided text, except for a note excluding quotes by Dr. Walid Abi-Saab from incorporation into certain registration statements.

Guidance, Outlook, and Risks

No guidance, outlook, management commentary, or specific risk factors are detailed in the text of this Form 6-K. The document focuses on regulatory compliance regarding the incorporation of the press release into existing Registration Statements on Forms F-3 and S-8.

Investor Verification Checklist

  • Verify the actual content of the February 2, 2022 press release (Exhibit 99.1) to understand the material event triggering this filing.
  • Confirm the correct registrant name is Galapagos NV, noting the discrepancy with the metadata provided.
  • Review the referenced Registration Statements (Forms F-3 and S-8) to see how the press release information is integrated.
  • Check for any subsequent filings that may provide the financial context or operational details omitted from this specific Form 6-K.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.